133 related articles for article (PubMed ID: 8328364)
1. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients.
Suraniti S; Berrut G; Marre M; Fressinaud P
Am J Cardiol; 1993 Jun; 71(17):28E-31E. PubMed ID: 8328364
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Morgan TO; Louis WJ; MacDonald GJ; Conway EL; Bartholomeusz LC; Anderson AI; Cameron DP; Donnelly T; Frewin DB; Hooper MJ
Am J Med; 1992 Apr; 92(4B):73S-78S. PubMed ID: 1580284
[TBL] [Abstract][Full Text] [Related]
3. A double blind comparison of perindopril and atenolol in essential hypertension.
Thurston H; Mimran A; Zanchetti A; Creytens G; Rorive G; Brown CL; Santoni JP
J Hum Hypertens; 1990 Oct; 4(5):547-52. PubMed ID: 2283644
[TBL] [Abstract][Full Text] [Related]
4. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril.
Poggi L; Renucci JF; Denolle T
Can J Cardiol; 1994 Nov; 10 Suppl D():21D-24D. PubMed ID: 7954035
[TBL] [Abstract][Full Text] [Related]
5. Long-term acceptability of perindopril: European multicenter trial on 856 patients.
Degaute JP; Leeman M; Desche P
Am J Med; 1992 Apr; 92(4B):84S-90S. PubMed ID: 1580287
[TBL] [Abstract][Full Text] [Related]
6. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.
Alcocer L; Campos C; Bahena JH; Nacaud A; Parra Carillo J; Calvo C; Weber C; Lerebours G; Mickalonis L; Villahermosa MT
Cardiovasc Drugs Ther; 1995 Jun; 9(3):431-6. PubMed ID: 8527353
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and acceptability of perindopril in essential hypertension.
Sukonthasarn A; Ratanaprakarn R; Koanantakul B; Ngam-Ukos P
J Med Assoc Thai; 1994 Jun; 77(6):281-7. PubMed ID: 7869013
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension.
Andrejak M; Santoni JP; Carré A; Deruyttere M; Magometschnigg D; Gotzen R; Stumpe KO
Fundam Clin Pharmacol; 1991; 5(3):185-92. PubMed ID: 1682228
[TBL] [Abstract][Full Text] [Related]
9. [Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice].
Fressinaud P; Berrut G; Gallois H
Ann Cardiol Angeiol (Paris); 1993 Jan; 42(1):51-9. PubMed ID: 8480986
[TBL] [Abstract][Full Text] [Related]
10. Perindopril: an updated review of its use in hypertension.
Hurst M; Jarvis B
Drugs; 2001; 61(6):867-96. PubMed ID: 11398915
[TBL] [Abstract][Full Text] [Related]
11. Assessment of antihypertensive efficacy of perindopril: results of double-blind multicenter studies versus reference drugs.
Thurston H; Desche P
J Cardiovasc Pharmacol; 1991; 18 Suppl 7():S45-9. PubMed ID: 1725202
[TBL] [Abstract][Full Text] [Related]
12. [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study].
Widimský J; Fedelesová V; Uhlír O
Vnitr Lek; 1995 Jul; 41(7):441-4. PubMed ID: 7571476
[TBL] [Abstract][Full Text] [Related]
13. Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril.
Forette F; McClaran J; Delesalle MC; Hervy MP; Bouchacourt P; Henry-Amar M; Santoni JP
Clin Exp Hypertens A; 1989; 11 Suppl 2():587-603. PubMed ID: 2691131
[TBL] [Abstract][Full Text] [Related]
14. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
Gasowski J; Wilkins A; Drzewoski J; Kłoś J; Gaciong Z; Kabat M; Grodzicki T
Cardiol J; 2010; 17(3):259-66. PubMed ID: 20535716
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly.
Leenen FH; Tanner J; McNally CF
J Hum Hypertens; 2000 May; 14(5):321-5. PubMed ID: 10822319
[TBL] [Abstract][Full Text] [Related]
16. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
Overlack A; Adamczak M; Bachmann W; Bönner G; Bretzel RG; Derichs R; Krone W; Lederle RM; Reimann HJ; Zschiedrich H
Am J Med; 1994 Aug; 97(2):126-34. PubMed ID: 8059778
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Fogari R; Zoppi A; Lazzari P; Preti P; Mugellini A; Corradi L; Lusardi P
J Cardiovasc Pharmacol; 1998 Oct; 32(4):616-20. PubMed ID: 9781930
[TBL] [Abstract][Full Text] [Related]
18. The safety and acceptability of perindopril.
Brown CL
J Hum Hypertens; 1990 Oct; 4 Suppl 4():51-5; discussion 55-6. PubMed ID: 2283654
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Results of a long-term open study in 320 patients.
Desche P; Antony I; Lerebours G; Violet I; Robert S; Weber C
Am J Cardiol; 1993 Jun; 71(17):61E-68E. PubMed ID: 8328369
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
Thurston H
Clin Exp Pharmacol Physiol Suppl; 1992; 19():67-71. PubMed ID: 1395119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
